| 0.902 | 0.004 | 0.902 | Analgesic | | |
| 0.855 | 0.003 | 0.855 | Glutamate receptor antagonist | | |
| 0.781 | 0.005 | 0.781 | Immunomodulator | | |
| 0.785 | 0.018 | 0.785 | Antiinflammatory | | |
| 0.727 | 0.002 | 0.727 | NMDA 2C receptor antagonist | | |
| 0.713 | 0.004 | 0.713 | Apoptosis antagonist | | |
| 0.693 | 0.015 | 0.693 | Cyclophilin D inhibitor | | |
| 0.679 | 0.007 | 0.679 | Nootropic | | |
| 0.655 | 0.003 | 0.655 | NMDA receptor antagonist | | |
| 0.583 | 0.003 | 0.583 | NMDA 2B receptor antagonist | | |
| 0.582 | 0.009 | 0.582 | Amyloid beta aggregation inhibitor | | |
| 0.564 | 0.003 | 0.564 | NMDA 2 receptor antagonist | | |
| 0.57 | 0.035 | 0.57 | Transcription factor NF kappa B inhibitor | | |
| 0.533 | 0.009 | 0.533 | Vasodilator | | |
| 0.488 | 0.005 | 0.488 | Platelet adhesion inhibitor | | |
| 0.482 | 0.003 | 0.482 | NMDA 2A receptor antagonist | | |
| 0.471 | 0.001 | 0.471 | Glutamate release inhibitor | | |
| 0.452 | 0.03 | 0.452 | Spasmolytic | | |
| 0.402 | 0.008 | 0.402 | Lipocortins synthesis antagonist | | |
| 0.432 | 0.039 | 0.432 | 5 Hydroxytryptamine release stimulant | | |
| 0.388 | 0.003 | 0.388 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitor | | |
| 0.398 | 0.022 | 0.398 | Sigma receptor agonist | | |
| 0.425 | 0.054 | 0.425 | Immunosuppressant | | |
| 0.358 | 0.005 | 0.358 | Acetylcholine nicotinic antagonist | | |
| 0.353 | 0.003 | 0.353 | Protein kinase B beta inhibitor | | |
| 0.44 | 0.096 | 0.44 | Apoptosis agonist | | |
| 0.329 | 0.015 | 0.329 | Cholinergic | | |
| 0.389 | 0.082 | 0.389 | Antibacterial | | |
| 0.32 | 0.028 | 0.32 | Ca(v)3.3 blocker | | |
| 0.323 | 0.034 | 0.323 | 5 Hydroxytryptamine uptake stimulant | | |
| 0.326 | 0.057 | 0.326 | Sodium/bile acid cotransporter inhibitor | | |
| 0.284 | 0.034 | 0.284 | TRKC antagonist | | |
| 0.299 | 0.052 | 0.299 | Antiamyloidogenic | | |
| 0.248 | 0.006 | 0.248 | Neuronal nicotinic receptor antagonist | | |
| 0.224 | 0.005 | 0.224 | Epoxide hydrolase inhibitor | | |
| 0.321 | 0.103 | 0.321 | GABA C receptor rho-3 antagonist | | |
| 0.226 | 0.008 | 0.226 | Dopamine agonist | | |
| 0.221 | 0.004 | 0.221 | Protein kinase B alpha inhibitor | | |
| 0.281 | 0.065 | 0.281 | DNA damaging | | |
| 0.214 | 0.004 | 0.214 | Acetylcholine release stimulant | | |
| 0.246 | 0.041 | 0.246 | Neurotrophic factor enhancer | | |
| 0.21 | 0.005 | 0.21 | Cannabinoid CB2 receptor antagonist | | |
| 0.223 | 0.027 | 0.223 | Acetylcholinesterase inhibitor | | |
| 0.238 | 0.045 | 0.238 | P-glycoprotein inhibitor | | |
| 0.292 | 0.1 | 0.292 | Calcium channel activator | | |
| 0.197 | 0.021 | 0.197 | GABA C receptor agonist | | |
| 0.196 | 0.021 | 0.196 | Expectorant | | |
| 0.179 | 0.005 | 0.179 | Toll-Like receptor 7 antagonist | | |
| 0.244 | 0.07 | 0.244 | DNA synthesis inhibitor | | |
| 0.248 | 0.076 | 0.248 | Superoxide dismutase inhibitor | | |
| 0.189 | 0.02 | 0.189 | Beta amyloid protein antagonist | | |
| 0.199 | 0.034 | 0.199 | Arachidonic acid antagonist | | |
| 0.313 | 0.151 | 0.313 | 5 Hydroxytryptamine release inhibitor | | |
| 0.186 | 0.035 | 0.186 | Acetylcholine antagonist | | |
| 0.186 | 0.036 | 0.186 | Cholinergic antagonist | | |
| 0.163 | 0.012 | 0.163 | Cannabinoid receptor antagonist | | |
| 0.235 | 0.084 | 0.235 | Tyrosine 3 hydroxylase inhibitor | | |
| 0.327 | 0.178 | 0.327 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | | |
| 0.168 | 0.022 | 0.168 | GABA C receptor antagonist | | |
| 0.175 | 0.03 | 0.175 | Adenylate cyclase stimulant | | |
| 0.237 | 0.095 | 0.237 | Gastrin inhibitor | | |
| 0.161 | 0.022 | 0.161 | Ca2+-transporting ATPase inhibitor | | |
| 0.208 | 0.076 | 0.208 | Psychostimulant | | |
| 0.146 | 0.014 | 0.146 | Cannabinoid receptor agonist | | |
| 0.153 | 0.021 | 0.153 | Nitric-oxide synthase inhibitor | | |
| 0.149 | 0.018 | 0.149 | Anabolic | | |
| 0.138 | 0.007 | 0.138 | Protease activated receptor 1 antagonist | | |
| 0.133 | 0.004 | 0.133 | Vascular adhesion protein 1 inhibitor | | |
| 0.137 | 0.012 | 0.137 | Cannabinoid CB2 receptor agonist | | |
| 0.123 | 0.006 | 0.123 | Dipeptidyl peptidase inhibitor | | |
| 0.119 | 0.004 | 0.119 | Dipeptidyl peptidase IV inhibitor | | |
| 0.176 | 0.068 | 0.176 | Antipruritic | | |
| 0.128 | 0.022 | 0.128 | Inducible nitric-oxide synthase inhibitor | | |
| 0.201 | 0.098 | 0.201 | RNA-directed DNA polymerase inhibitor | | |
| 0.116 | 0.014 | 0.116 | 5 Hydroxytryptamine 3 antagonist | | |
| 0.252 | 0.155 | 0.252 | Antiobesity | | |
| 0.103 | 0.007 | 0.103 | Nitric oxide donor | | |
| 0.148 | 0.056 | 0.148 | Alpha-N-acetylglucosaminidase inhibitor | | |
| 0.102 | 0.011 | 0.102 | Bombesin 3 receptor antagonist | | |
| 0.114 | 0.026 | 0.114 | Opioid kappa receptor antagonist | | |
| 0.103 | 0.019 | 0.103 | Glycine receptor agonist | | |
| 0.093 | 0.01 | 0.093 | 5-Alpha-reductase inhibitor | | |
| 0.092 | 0.014 | 0.092 | Glutamate (mGluR6) antagonist | | |
| 0.143 | 0.068 | 0.143 | Pregnane X receptor agonist | | |
| 0.15 | 0.077 | 0.15 | Interferon gamma antagonist | | |
| 0.108 | 0.036 | 0.108 | Ornithine decarboxylase inhibitor | | |
| 0.09 | 0.018 | 0.09 | Sigma receptor antagonist | | |
| 0.158 | 0.089 | 0.158 | Nitric oxide antagonist | | |
| 0.192 | 0.125 | 0.192 | Immunostimulant | | |
| 0.083 | 0.021 | 0.083 | Protease activated receptor antagonist | | |
| 0.147 | 0.086 | 0.147 | Melanin inhibitor | | |
| 0.182 | 0.123 | 0.182 | Nitric-oxide synthase stimulant | | |
| 0.094 | 0.037 | 0.094 | Na+ K+ transporting ATPase inhibitor | | |
| 0.119 | 0.062 | 0.119 | Microtubule formation inhibitor | | |
| 0.16 | 0.104 | 0.16 | Anesthetic general | | |
| 0.082 | 0.028 | 0.082 | Carbamoyl phosphate synthetase inhibitor | | |
| 0.093 | 0.039 | 0.093 | Glycine receptor antagonist | | |
| 0.108 | 0.056 | 0.108 | Adenylate kinase inhibitor | | |
| 0.109 | 0.062 | 0.109 | Ferrochelatase inhibitor | | |
| 0.052 | 0.006 | 0.052 | Carboxypeptidase B inhibitor | | |
| 0.074 | 0.028 | 0.074 | Androgen agonist | | |
| 0.084 | 0.039 | 0.084 | Phosphofructokinase-1 inhibitor | | |
| 0.107 | 0.063 | 0.107 | DOPA decarboxylase inhibitor | | |
| 0.152 | 0.109 | 0.152 | Succinate dehydrogenase inhibitor | | |
| 0.172 | 0.13 | 0.172 | 5 Hydroxytryptamine 3E antagonist | | |
| 0.046 | 0.006 | 0.046 | Glutamate (mGluR3) agonist | | |
| 0.063 | 0.023 | 0.063 | Alpha-mannosidase inhibitor | | |
| 0.085 | 0.045 | 0.085 | Nicotinic alpha4beta2 receptor antagonist | | |
| 0.045 | 0.011 | 0.045 | Dipeptidyl peptidase II inhibitor | | |
| 0.04 | 0.007 | 0.04 | Purinergic P2Y15 antagonist | | |
| 0.046 | 0.014 | 0.046 | Glutamate (mGluR8) agonist | | |
| 0.04 | 0.011 | 0.04 | Epoxide hydrolase 1 inhibitor | | |
| 0.037 | 0.012 | 0.037 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | | |
| 0.06 | 0.036 | 0.06 | Lipocortins synthesis agonist | | |
| 0.09 | 0.066 | 0.09 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | | |
| 0.061 | 0.037 | 0.061 | Botulinum neurotoxin type A inhibitor | | |
| 0.143 | 0.12 | 0.143 | Neurotensin receptor agonist | | |
| 0.042 | 0.019 | 0.042 | Glutamate (mGluR3) antagonist | | |
| 0.05 | 0.027 | 0.05 | Adenylate cyclase 1 inhibitor | | |
| 0.156 | 0.134 | 0.156 | Aldehyde oxidase inhibitor | | |
| 0.093 | 0.072 | 0.093 | GABA C receptor rho-1 antagonist | | |
| 0.082 | 0.061 | 0.082 | Estrogen-related receptor beta agonist | | |
| 0.057 | 0.036 | 0.057 | Acyl-CoA dehydrogenase inhibitor | | |
| 0.043 | 0.024 | 0.043 | Dopamine D5 agonist | | |
| 0.084 | 0.066 | 0.084 | NADH dehydrogenase inhibitor | | |
| 0.045 | 0.027 | 0.045 | Guanylate cyclase inhibitor | | |
| 0.074 | 0.057 | 0.074 | Keratolytic | | |
| 0.022 | 0.006 | 0.022 | NMDA receptor phencyclidine site antagonist | | |
| 0.155 | 0.139 | 0.155 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | | |
| 0.19 | 0.174 | 0.19 | Cholesterol antagonist | | |
| 0.054 | 0.039 | 0.054 | Sphingosine kinase 2 inhibitor | | |
| 0.021 | 0.006 | 0.021 | Telomerase stimulant | | |
| 0.033 | 0.019 | 0.033 | RNA-directed RNA polymerase stimulant | | |
| 0.14 | 0.127 | 0.14 | Phospholipase C inhibitor | | |
| 0.073 | 0.06 | 0.073 | GABA B receptor agonist | | |
| 0.045 | 0.032 | 0.045 | Mannosidase inhibitor | | |
| 0.017 | 0.004 | 0.017 | Carboxypeptidase B2 inhibitor | | |
| 0.037 | 0.025 | 0.037 | Arginase inhibitor | | |
| 0.034 | 0.022 | 0.034 | Glucocorticoid antagonist | | |
| 0.015 | 0.004 | 0.015 | 3 Beta-hydroxy-delta 5-steroid dehydrogenase inhibitor | | |
| 0.028 | 0.017 | 0.028 | Hedgehog signaling activator | | |
| 0.05 | 0.043 | 0.05 | Nicotinic alpha3beta2 receptor antagonist | | |
| 0.077 | 0.069 | 0.077 | Androgen antagonist | | |
| 0.129 | 0.121 | 0.129 | CF transmembrane conductance regulator agonist | | |
| 0.02 | 0.013 | 0.02 | 5-Alpha-reductase 2 inhibitor | | |
| 0.054 | 0.048 | 0.054 | Pregnane X receptor antagonist | | |
| 0.037 | 0.031 | 0.037 | Membrane dipeptidase inhibitor | | |
| 0.032 | 0.029 | 0.032 | Purinergic P2X7 antagonist | | |
| 0.012 | 0.009 | 0.012 | Glutamate (mGluR6) agonist | | |
| 0.035 | 0.033 | 0.035 | Potassium channel Kv1.1 blocker | | |
| 0.038 | 0.036 | 0.038 | Kainate receptor agonist | | |
| 0.079 | 0.078 | 0.079 | Granulocyte macrophage colony stimulating factor agonist | | |
| 0.065 | 0.064 | 0.065 | Glutamate dehydrogenase inhibitor | | |
| 0.023 | 0.022 | 0.023 | Purinergic P2X agonist | | |
| 0.076 | 0.075 | 0.076 | Opioid antagonist | | |
| 0.018 | 0.017 | 0.018 | Progesterone receptor B antagonist | | |